La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Envista Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Envista Holdings..

Envista Holdings (NYSE:NVST) Azioni, Catena delle Opzioni

Envista Holdings

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.

Envista Holdings Corporation Common Stock

Envista Holdings Corp

HC Wainwright &amp; Co. analyst Edward White reiterates 60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

SXTP

HC Wainwright & Co. Reiterates Neutral on 60 Degreesto Neutral

Wells Fargo analyst Jason Haas maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Underweight and lowers the price target from $470 to $460.

Price Target

Wells Fargo Maintains Underweight on Gartner, Lowers Price Target to $460

Wells Fargo analyst Jason Haas maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Overweight and lowers the price target from $325 to $321.

Wells Fargo Maintains Overweight on Equifax, Lowers Price Target to $321

WIIM

Constellation Brands shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY25 adjusted EPS guidance and sales growth outlook.

Trading Ideas

IBCP

Independent Bank Increases Quarterly Cash Dividend From $0.24 To $0.26

Wells Fargo analyst Yanan Zhu maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Overweight and lowers the price target from $70 to $60.

NTLA

Wells Fargo Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $60

BMO Capital analyst Kostas Biliouris maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Outperform and lowers the price target from $70 to $50.

BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50

BMO Capital analyst James Thalacker maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Outperform and lowers the price target from $108 to $100.

BMO Capital Maintains Outperform on American Electric Power, Lowers Price Target to $100

The December jobs report jolted financial markets during early Friday trading. Stronger-than-expected employment growth and a drop in the unemployment rate to 4.1% raised fears the Federal Reserve may hold off on cutting interest rates <a href="https://www.benzinga.com/news/econ-s">for most of 2025.</a>
<h3 class="wp-block-heading">December Jobs Report Fuels Fed Hawkishness: Dollar Soars, Yields Jump </h3>
The U.S. economy added 256,000 new jobs last month, marking an acceleration from the downwardly revised 212,000 jobs added in November and sharply outpacing economist forecasts of 160,000, as tracked by TradingEconomics.
The December reading represented the strongest monthly job growth since March 2024, underscoring the continued resilience of the U.S. economy despite high interest rates and resurgent inflationary pressures.
The unemployment rate ticked down from 4.2%to 4.1% in November, defying expectations of no change. Wages rose broadly in line with expectations, with average hourly earnings increasing 0.3% month-over-month, slowing slightly from November&#8217;s 0.4%. On a year-over-year basis, wages climbed 3.9%, marginally below the 4% forecast.
Fed fund futures showed a steep decline in the probability of a March rate cut, with implied odds dropping to just 26%, down from 43% a day earlier, according to CME&#8216;s FedWatch tool.
Treasury yields rose sharply across the curve, reflecting a repricing of interest rate expectations. 
The two-year yield, closely tied to Federal Reserve policy expectations, jumped 11 basis points to 4.37%. The 10-year yield surged 10 basis points to 4.79%, its highest level since November 2023.
Notably, the most striking move came in the 30-year yield, which breached the 5% mark for the first time since October 2023. Before that, the last time 30-year yields surpassed this milestone was in August 2007. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) dropped 1.2% in premarket trading, highlighting the market's sensitivity to long-term rates.
The U.S. Dollar Index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), surged 0.5% to 109.70, a level last seen in late October 2022. 
The greenback climbed 0.4% against the Japanese yen and 0.6% versus the euro, pushing the euro-dollar pair to a fresh 27-month low of 1.0250. The Sterling wasn&#8217;t spared, falling 0.7% to a 15-month low against the dollar.
<h3 class="wp-block-heading">Stocks Slump Across The Board</h3>
Futures on major U.S. indices were down 1% across the board, as the prospect of higher-for-longer interest rates rattled investors. All S&amp;P 500 sectors, except energy, traded in the negative premarket Friday.
Real estate, tracked by the Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>), and technology, represented by the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), both sank 1.4%. 
Rate-sensitive sectors such as real estate and growth-heavy tech bore the brunt of the selloff as higher yields weighed on long-duration assets.
The one standout sector was energy, with the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) climbing 1.3%.
<h3 class="wp-block-heading">Major Premarket Movers</h3>
Among energy giants, Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) gained 1.67% to $152.81, Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) rose 1.57% to $108.61 and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) advanced 1.43% to $103.07, benefiting from a 3% spike in oil prices after Reuters reported thet U.S. is mulling stronger sanctions on Russia&#8217;s oil sector.
In contrast, rate-sensitive mega-cap tech stocks dragged the market lower. 
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 2.51% to $136.59, Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 2.92% to $118.28 and American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) plunged 3.93% to $68.63, leading losses among financials.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42901085/us-2025-recession-odds-plummet-good-news-or-warning-sign">US 2025 Recession Odds Plummet: Good News Or Warning Sign?</a></li>
</ul>
Photo via Shutterstock.

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Markets

ETFs

NVDA

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

XLRE

Dollar Soars To 27-Month Highs, 30-Year Yields Hit 5%, Stocks Tumble As Jobs Report, Oil Spike Darken Fed's Interest Rate Cut Hopes

<ul>
<li>NVDA</li>
<li>AMD</li>
<li>TSLA</li>
<li>MVST</li>
<li>MSTR</li>
<li>RGTI</li>
<li>FUBO</li>
<li>QQQ</li>
<li>CVNA</li>
<li>RKLB</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CVNA

FUBO

MSTR

MVST

RGTI

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of January 10, 2025 (Via Swaggy Stocks)

RZLV

Shoeby To Use Rezolve Ai Technology

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) on Friday said it expects significant booking growth<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42908809/d-wave-announces-fiscal-year-2024-bookings-will-exceed-23-million-up-approximately-120-over-fiscal" rel="noreferrer noopener"> for fiscal year 2024.</a>
The company reported that its bookings will exceed $23 million, marking a 120% increase over fiscal year 2023.
The company&#8217;s CEO&nbsp;Alan Baratz has criticized&nbsp;Nvidia Corp. CEO&nbsp;Jensen Huang for his comments regarding the timeline for achieving practical quantum<a target="_blank" href="https://www.benzinga.com/25/01/42892470/jensen-huang-is-dead-wrong-about-quantum-computing-d-wave-ceo-fires-back-at-nvidia-boss-happy-to-meet-with-jensen-any-time-any-place-to-help-fill-in-these-gaps" rel="noreferrer noopener"> computing, saying he is &#8220;dead wrong.&#8221;</a>
Huang&#8217;s remarks during Nvidia&#8217;s analyst day, suggesting a 15 to 30-year wait for &#8220;very useful quantum computers,&#8221; have&nbsp;sparked a heated debate&nbsp;in the tech community.
A key driver of D-Wave&#8217;s growth is the first-ever customer purchase of the D-Wave Advantage system, a quantum computer with over 5,000 qubits.
This sale signals a major expansion of D-Wave&#8217;s revenue model, as it begins offering on-premise quantum systems in addition to its cloud services.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42900817/quantum-stocks-regetti-computing-ionq-d-wave-poised-to-open-higher-after-nvidia-ceo-comments-drove-huge-losses" rel="noreferrer noopener">Quantum Stocks Regetti Computing, IonQ, D-Wave Poised To Open Higher After Nvidia CEO Comments Drove Huge Losses</a>
The Advantage system provides customers full access to its capabilities, allowing them to modify system parameters and integrate it into their own infrastructure.
D-Wave&#8217;s growing customer base, including research centers and businesses, highlights the increasing demand for quantum computing solutions, particularly for addressing challenges in AI power consumption and national security.
Additionally, D-Wave disclosed that its fiscal fourth-quarter 2024 bookings will reach at least $18 million, a staggering 500% increase over the same period last year.
The company also ended the fiscal year with a strong cash position of approximately $178 million.
Price Action: QBTS shares are trading higher by 0.66% to $6.14 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42908495/us-stocks-to-open-on-a-tentative-note-as-traders-remain-cautious-ahead-of-fridays-crucial-jobs-data" target="_blank" rel="noreferrer noopener">US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday&#8217;s Crucial Jobs Data</a></li>
</ul>
Photo via Shutterstock.

Guidance

Movers

General

QBTS

What's Going On With D-Wave Quantum Stock Today?

Pennsylvania Sen. <a href="https://www.benzinga.com/topic/john-fetterman">John Fetterman</a> will become the first Democrat to join the slew of politicians and billionaire businesspeople who are making the trek to meet with President-elect Donald Trump at his Mar-a-Lago home <a href="https://www.benzinga.com/topic/mar-a-lago">in Palm Beach, Florida</a>.
Fetterman said in a statement Thursday that Trump invited him to meet and that he accepted.
"I'm the senator for all Pennsylvanians — not just Democrats in Pennsylvania," he said in a statement, <a href="https://www.cbsnews.com/news/fetterman-trump-mar-a-lago/" target="_blank" rel="noreferrer noopener">first</a> reported by CBS News. "I've been clear that no one is my gatekeeper. I will meet with and have a conversation with anyone if it helps me deliver for Pennsylvania and the nation."
The meeting is expected to take place this weekend.
The trip marks Fetterman's transition from a leading supporter of President Joe Biden into a "Trump-friendly lawmaker," as <a href="https://apnews.com/article/john-fetterman-donald-trump-maralago-d3bf4398cf71b7a66885f5b910dec9f6">described</a> by the Associated Press, following Trump&#8217;s victory in the battleground state of Pennsylvania.
<h2 class="wp-block-heading">From Bitter Enemies To Almost Friends</h2>
Fetterman <a href="https://www.benzinga.com/markets/cannabis/22/05/27268902/breaking-john-fetterman-wins-pennsylvania-democratic-senate-primary">was elected </a>to the Senate in 2022 in a knockdown battle against multimillionaire TV host Dr. Mehmet Oz, widely viewed as hand-picked by Trump. Things got nasty when Oz <a href="https://www.benzinga.com/markets/cannabis/22/08/28710156/dr-oz-campaign-again-mocks-john-fetterman-over-stroke-politics-are-dirty-but-have-we-sunk-to-a-n">publicly mocked Fetterman </a>on several occasions for refusing to debate him after the former Lt. governor of Pennsylvania suffered a stroke that affected his speech.
Then, the conflict intensified between Trump and Fetterman. At the time, <a href="https://www.benzinga.com/markets/cannabis/22/09/28749697/maga-rally-trump-calls-for-death-to-drug-dealers-says-fetterman-uses-hard-drugs-and-wears-dirty-" target="_blank" rel="noopener">Trump accused Fetterman</a> of supporting "taxpayer-funded drug dens and the complete decriminalization of illegal drugs, including heroin, cocaine, crystal meth, and ultra-lethal fentanyl, and by the way, he takes them himself." For the record, Fetterman does <a href="https://www.benzinga.com/markets/cannabis/23/11/35959706/fetterman-says-cannabis-legalization-is-inevitable-despite-some-republican-opposition">support the legalization</a> of cannabis.
<h2 class="wp-block-heading">Immigration And The Southern Border: Almost A Bipartisan Issue</h2>
Fetterman was the first Democrat to sponsor the Laken Riley Act, which <a href="https://www.benzinga.com/general/24/03/37625012/donald-trump-says-laken-riley-would-be-alive-today-under-his-administration-as-biden-apologizes-for">came up often</a> during Trump's 2024 presidential campaign. The legislation, named after a nursing student who was killed by an undocumented&nbsp;Venezuelan immigrant, would compel the federal government to detain noncitizens convicted or charged with burglary, larceny, theft or shoplifting.
As of Thursday, with a vote of 84-9 with 32 Democrats and one independent&nbsp;joining all 51 Republicans, <a href="https://www.nbcnews.com/politics/congress/senate-laken-riley-act-vote-illegal-immigration-rcna186775">reported</a> NBC News, the bill cleared the threshold to move on to the GOP-controlled Senate.
&#8220;We absolutely need to have a secure border, and I have always also been incredibly supportive and protective for Dreamers,&#8221; Fetterman <a href="https://www.washingtonexaminer.com/opinion/columnists/3280616/john-fetterman-laken-riley-act-common-sense/">told</a> the Washington Examiner on Tuesday, referring to young people who were born in the U.S. to undocumented parents and therefore may face deportation.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42902618/canadian-official-claps-back-at-trumps-51st-state-comments-offers-to-buy-these-two-american-states">Canadian Official Claps Back At Trump&#8217;s 51st State Comments, Offers To Buy These Two American States</a></li>
</ul>
Photo of Fetterman by OogImages on Shutterstock

Cannabis

Government

Politics

John Fetterman First Democratic Lawmaker To Accept Trump Invitation To Mar-a-Lago Since 2024 Election

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 14.96% on an annualized basis producing an average annual return of 27.44%. Currently, Iron Mountain has a market capitalization of $29.99 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $333.50 today based on a price of $102.20 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736518523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Short Sellers

TMDX

Watching TransMedics Shares, Scorpion Capital Publishes Report On Co. With $0 PT

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $555 to $460.

VRTX

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1050 to $900.

REGN

Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $900

TLRY

Tilray Brands shares are trading lower after the company reported worse-than-expected Q2 revenue results.

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing volatile trading on Friday, briefly regaining the $95,000 market before slumping below $94,000 on a hotter-than-expected j<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">obs market report</a>.
What Happened: The apex cryptocurrency is trading down 2% over the past 24 hours, having visited the $92,000 and $95,000 marks within this timeframe.
Prominent technical analyst DonAlt remains somewhat upbeat about its prospects, despite current volatility.
In his latest technical analysis podcast <a href="https://www.youtube.com/watch?v=x-W-JUZ9jLo">published</a> on Wednesday, DonAlt acknowledged that recent pullbacks have caused concern but stressed that Bitcoin's high timeframe charts remain strong. 
He suggests the reaction to recent dips might be overblown, stating, "Bitcoin still looks quite decent. I think $150,000 would already be significant this cycle."
He also underscored that the maturing market might not deliver the explosive gains seen in previous cycles, urging investors to temper expectations.
Regarding Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), DonAlt pointed to $2,900-$3,000 as a critical support level. 
He doesn't consider Ethereum "cooked" unless it breaks below this range. 
XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), meanwhile, stands out as a top performer. He praised its current chart, saying, "It's just a good-looking chart."
On the topic of FTX payouts, DonAlt suggested that the potential market impact is limited, as many large claim holders have already sold their stakes.
He also emphasized that the crypto market has matured, making sharp corrections less frequent but also reducing the likelihood of dramatic upward moves.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
What's Next: Looking ahead, DonAlt predicts the current market cycle is nearing its conclusion, estimating it could wrap up in a few months. 
However, he remains hopeful for an "aggressive last leg" of growth before the cycle ends.
He cited former President Donald Trump's pro-crypto stance as a potential driver for market expansion, noting, "Trump is trying to pump this market, and I think it's still small enough for him to influence."
DonAlt urged caution, emphasizing the importance of managing risk and securing profits, as the market might not replicate previous cycles&#8217; meteoric gains.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Bitcoin Fights To Regain $94,000: What Does Technical Analysis Say?

Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Equal-Weight and lowers the price target from $190 to $165.

BIIB

Wells Fargo Maintains Equal-Weight on Biogen, Lowers Price Target to $165

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Envista Holdings (NVST – Research Report) yesterday and set a price target of $24...

Stifel Nicolaus Remains a Buy on Envista Holdings (NVST)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista Holdings...

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST)

Assessing MedTech impact from potential China tariffs

BlackRock Event Driven Equity Fund Q3 2024 Commentary

Mizuho analyst Steven Valiquette initiated coverage of Envista (NVST) with an Underperform rating and $20 price target As a diverse dental/orthodon...

Envista initiated with an Underperform at Mizuho

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), E...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Envista Holdings (NVST) and UnitedHealth (UNH)

Tracking John Rogers' Ariel Investments Portfolio - Q3 2024 Update

NeuroPace (NPCE) announced the appointment of Scott Huennekens to its board of directors, effective January 6. Huennekens currently serves as chair...

NeuroPace appoints Scott Huennekens to board

Analyst Jonathan Block of Stifel Nicolaus maintained a Buy rating on Envista Holdings (NVST – Research Report), retaining the price target of $24.0...

Envista Holdings: Positive Momentum and Financial Strengthening Under New Management

ALEC

ALGN

BOKF

CHKP

COHR

CPRI

CTLT

DOCS

GDRX

GEHC

GNRC

GNTX

HSIC

HYPR

LFMD

MASI

MGRB

MGRD

MGRE

MSFT

MSGE

MSGS

NISTF

NONOF

NPCE

NPSCY

NTRS

NTRSO

NVST

PDCO

PSTG

REZI

RNAC

SAEF

SOLV

SPHR

TALK

TNDM

TRMB

VEEV

VLTO

XRAY

ZBRA

Press Releases

Envista Announces Participation in Baird's 2024 Global Healthcare Conference

DEXIS Digital Ecosystem Expands With Three New Innovations To Streamline and Connect Dental Workflows

Envista Schedules Third Quarter 2024 Earnings Call

Earnings

Envista Reports Third Quarter 2024 Results

Envista Announces Participation in Evercore HealthCONx Conference

Envista Announces Release of 2023 Sustainability Report

Events

DEXIS Attends ADF, Showcases Award-Winning Solutions

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

Envista Announces Participation in 43rd Annual J.P. Morgan Healthcare Conference

Management

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

Comments

Envista Holdings

Envista Holdings (NVST) Opzioni

Envista Holdings (NYSE:NVST) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO